Nucleai Closes $33 Million Series B Financing To Advance Spatial Biology Platform For Drug Research, Development And Diagnostics
Amount Raised
$33 Million
Round Type
Series B
Tel AvivBiotechnologySoftwareData And AnalyticsHealth CareScience And EngineeringArtificial IntelligenceDescription
Nucleai, an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data, today announced that it had closed a $33 million Series B financing round, jointly led by Section 32 and Sanofi Ventures. Andy Harrison, Managing Partner at Section 32, and Cris De Luca, Global Head, Digital Investments at Sanofi Ventures, will join Nucleai’s Board of Directors. Section 32 Managing Partner Michael Pellini, MD, will join Nucleai’s Board as an observer. Nucleai plans to use the new funding to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations (CROs), who are applying its technology throughout translational research, clinical trials, and novel applications for drug discovery.
Quick answer
Nucleai raised $33 Million in a Series B round, dated March 22, 2022. Nucleai is based in Tel Aviv, Tel Aviv District, Israel.
- How much did Nucleai raise?
- Nucleai raised $33 Million in a Series B round on March 22, 2022.
- What does Nucleai do?
- Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data.
- Where is Nucleai based and how big is it?
- Nucleai is based in Tel Aviv, Tel Aviv District, Israel.
- Who are the decision-makers at Nucleai?
- Fundz holds 1 contact at Nucleai. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Data And Analytics and Science And Engineering around the same time
Companies in the same sectors as Nucleai that raised within 45 days of this round, from Fundz verified event records.
- IMPLICITY raised $23M (Funding Round) on April 27, 2022.
- Zephyr AI, Inc. raised $18M on April 4, 2022.
- Zephyr AI, Inc. raised $19M (Seed) on March 30, 2022.
- Engimmune Therapeutics raised an undisclosed amount (Seed) on May 3, 2022.
- Biofourmis raised an undisclosed amount on April 26, 2022.
- Unlearn raised $50M (Series B) on April 19, 2022.
Who to call at Nucleai, and when
A new round usually means Nucleai is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nucleai raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nucleai, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nucleai. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nucleai raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNucleai raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.